Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biogen | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to test the hypothesis that DMF can improve mitochondrial function in the brain of people with MS. The investigators will assess mitochondrial function in the cerebral grey matter by measuring PCr and ATP by 31P magnetic resonance spectroscopy (MRS) and NAA in NAWM by 1H MRS.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dimethyl fumarate | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in phosphocreatine (PCr) in cerebral grey matter | PCr levels evaluated by magnetic resonance spectroscopy | baseline and 6 months of treatment with Dimethyl Fumarate (DMF) |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in ATP in normal appearing white matter (NAWM) | ATP levels evaluated by magnetic resonance spectroscopy | baseline and 6 months of treatment with Dimethyl Fumarate |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in fatigue | as assessed by Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS), | baseline and 6 months of treatment with DMF |
| Changes in fatigue | as assessed by Modified Fatigue Impact Scale (MFIS), |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
21 patients with a diagnosis of relapsing-remitting multiple sclerosis
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rebecca Spain, MD, MSPH | Oregon Health and Science University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069462 | Dimethyl Fumarate |
| ID | Term |
|---|---|
| D005650 | Fumarates |
| D003998 | Dicarboxylic Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
Not provided
Not provided
Not provided
Not provided
Not provided
| baseline and 6 months of treatment with DMF |
| Changes in cognition | as assessed by the symbol digit modalities test (SDMT) | baseline and 6 months of treatment with DMF |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D009930 |
| Organic Chemicals |